Incidence and severity of SARS-CoV-2 infections in people With primary ciliary dyskinesia
Incidence and severity of SARS-CoV-2 infections in people With primary ciliary dyskinesia
Objectives: there is little data on SARS-CoV-2 in people with rare chronic diseases. We studied incidence and severity of SARS-CoV-2 and its risk factors in people with primary ciliary dyskinesia (PCD) from May 2020 to May 2022.
Methods: we used self-reported questionnaire data from the COVID-PCD study at baseline or during weekly follow-ups. We studied factors associated with SARS-CoV-2 and symptoms using Poisson regression.
Results: by May 2022, 728 people participated (40% male, median age 27 years; range 0–85). 87 (12%) reported SARS-CoV-2 at baseline or during follow-up and 62 people reported an incident SARS-CoV-2 infection during 716 person-years (incidence rate 9 per 100 person years). The strongest predictors for reporting SARS-CoV-2 were exposure during periods where Delta variant was dominant (IRR 4.52, 95% CI 1.92–10.6) and Omicron variants (IRR 13.3, 95% CI 5.2–33.8). Severity was mild; 12 (14%) were asymptomatic and 75 (86%) had symptoms among whom four were hospitalized. None needed intensive care and nobody died.
Conclusion: the COVID-PCD study participants did not have a higher incidence of SARS-CoV-2 infections nor higher risk of severe COVID-19 disease than people from the general population.
chronic lung disease, incidence, longitudinal, pandemic, rare disease
Pedersen, Eva S.L.
e97cafa7-8f99-4ec7-8ed6-5692a4cfaec0
Schreck, Leonie D.
cca15dce-a5f6-4efb-9bc7-877291594fd6
Goutaki, Myrofora
60fbeefc-dbb1-429c-b81a-3c35d368db64
Bellu, Sara
455c4cfa-3018-4a7d-867e-a9ecf098b894
Copeland, Fiona
17a56166-3d7c-443e-a598-e1320eacc13f
Lucas, Jane S.
5cb3546c-87b2-4e59-af48-402076e25313
Zwahlen, Marcel
34b45ce5-fec5-44cd-a33a-0a1ee25c946c
Kuehni, Claudia E.
ac67c925-ee32-429d-a3b5-c244daa314b4
17 August 2023
Pedersen, Eva S.L.
e97cafa7-8f99-4ec7-8ed6-5692a4cfaec0
Schreck, Leonie D.
cca15dce-a5f6-4efb-9bc7-877291594fd6
Goutaki, Myrofora
60fbeefc-dbb1-429c-b81a-3c35d368db64
Bellu, Sara
455c4cfa-3018-4a7d-867e-a9ecf098b894
Copeland, Fiona
17a56166-3d7c-443e-a598-e1320eacc13f
Lucas, Jane S.
5cb3546c-87b2-4e59-af48-402076e25313
Zwahlen, Marcel
34b45ce5-fec5-44cd-a33a-0a1ee25c946c
Kuehni, Claudia E.
ac67c925-ee32-429d-a3b5-c244daa314b4
Pedersen, Eva S.L., Schreck, Leonie D., Goutaki, Myrofora, Bellu, Sara, Copeland, Fiona, Lucas, Jane S., Zwahlen, Marcel and Kuehni, Claudia E.
(2023)
Incidence and severity of SARS-CoV-2 infections in people With primary ciliary dyskinesia.
International Journal of Public Health, 68, [1605561].
(doi:10.3389/ijph.2023.1605561).
Abstract
Objectives: there is little data on SARS-CoV-2 in people with rare chronic diseases. We studied incidence and severity of SARS-CoV-2 and its risk factors in people with primary ciliary dyskinesia (PCD) from May 2020 to May 2022.
Methods: we used self-reported questionnaire data from the COVID-PCD study at baseline or during weekly follow-ups. We studied factors associated with SARS-CoV-2 and symptoms using Poisson regression.
Results: by May 2022, 728 people participated (40% male, median age 27 years; range 0–85). 87 (12%) reported SARS-CoV-2 at baseline or during follow-up and 62 people reported an incident SARS-CoV-2 infection during 716 person-years (incidence rate 9 per 100 person years). The strongest predictors for reporting SARS-CoV-2 were exposure during periods where Delta variant was dominant (IRR 4.52, 95% CI 1.92–10.6) and Omicron variants (IRR 13.3, 95% CI 5.2–33.8). Severity was mild; 12 (14%) were asymptomatic and 75 (86%) had symptoms among whom four were hospitalized. None needed intensive care and nobody died.
Conclusion: the COVID-PCD study participants did not have a higher incidence of SARS-CoV-2 infections nor higher risk of severe COVID-19 disease than people from the general population.
Text
ijph-68-1605561 (1)
- Version of Record
More information
Accepted/In Press date: 27 July 2023
Published date: 17 August 2023
Additional Information:
Funding Information:
This research was funded by the Swiss National Foundation (SNF 320030B_192804/1), Switzerland, the Swiss Lung Association, Switzerland (2021-08_Pedersen), and also received support from the PCD Foundation, United States; the Verein Kartagener Syndrom und Primäre Ciliäre Dyskinesie, Germany; the PCD Support UK; and PCD Australia, Australia. MG receives funding from the Swiss National Science Foundation (PZ00P3_185923). Study authors participate in the BEAT-PCD Clinical Research Collaboration, supported by the European Respiratory Society.
Publisher Copyright:
Copyright © 2023 Pedersen, Schreck, Goutaki, Bellu, Copeland, Lucas, Zwahlen and Kuehni.
Keywords:
chronic lung disease, incidence, longitudinal, pandemic, rare disease
Identifiers
Local EPrints ID: 482207
URI: http://eprints.soton.ac.uk/id/eprint/482207
ISSN: 1661-8556
PURE UUID: 8f3de449-8b8f-4383-8ea5-c0e9d9b173c4
Catalogue record
Date deposited: 21 Sep 2023 16:38
Last modified: 18 Mar 2024 02:55
Export record
Altmetrics
Contributors
Author:
Eva S.L. Pedersen
Author:
Leonie D. Schreck
Author:
Myrofora Goutaki
Author:
Sara Bellu
Author:
Fiona Copeland
Author:
Marcel Zwahlen
Author:
Claudia E. Kuehni
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
